J&J Acquires Halda to Boost RIPTAC Based Oral Prostate Cancer Therapy

Johnson & Johnson (J&J) announced on November 17 a definitive agreement to acquire clinical-stage biotech Halda Therapeutics OpCo, Inc. (Halda) for $3.05 billion in cash.The acquisition strengthens J&J’s long-standing commitment to oncology and adds Halda’s RIPTAC™ platform and multiple drug candidates.

RIPTAC™-Based Oral Therapy Targets Prostate Cancer Proteins

The deal centers on Halda’s clinical-stage oral candidate HLD-0915 for prostate cancer treatment. J&J expects global new prostate cancer cases to reach 1.7 million by 2030, signaling rising medical demand.

HLD-0915 is designed for precise cancer cell killing and to overcome common multi-drug resistance. Its once-daily oral formulation aims to improve patient accessibility and adherence.

John C. Reed, J&J Executive VP of Innovative Medicines R&D, noted many cancer therapies lose effectiveness due to resistance. He highlights Halda’s mechanism could remain active when standard treatments fail. Early clinical trials show HLD-0915 demonstrates promising efficacy and good safety.

J&J plans to accelerate the ongoing Phase 1/2 trial (NCT06800313) toward later-stage development. The candidate leverages the RIPTAC™ platform, inducing specific protein interactions inside cancer cells for precise targeting. This technology may extend beyond oncology, with potential applications in other disease areas.

Breast, Lung, and Other Assets Strengthen J&J’s Multi-Cancer Pipeline

Beyond HLD-0915, J&J gains Halda’s early-stage assets for breast, lung, and other solid tumors. These candidates have unique mechanisms, complementing J&J’s existing oncology portfolio.

Jennifer Taubert, J&J Global Chair of Innovative Medicines, said the acquisition reinforces mid- to long-term growth. Integrating Halda’s platform, R&D, and talent with J&J’s global capabilities will accelerate innovative therapies.

While the oral prostate cancer drug is attractive, analysts suggest the key asset is Halda’s RIPTAC™ platform. Platform logic supports next-generation, highly selective small-molecule precision therapies with multiple indications.

As oncology moves toward personalized treatment, platform technologies like RIPTAC™ are seen as long-term growth drivers.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔